S. Claiborne Johnston
University of Texas at Austin
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by S. Claiborne Johnston.
Stroke | 2011
Karen L. Furie; Scott E. Kasner; Robert J. Adams; Gregory W. Albers; Ruth L. Bush; Susan C. Fagan; Jonathan L. Halperin; S. Claiborne Johnston; Irene Katzan; Walter N. Kernan; Pamela H. Mitchell; Bruce Ovbiagele; Yuko Y. Palesch; Ralph L. Sacco; Lee H. Schwamm; Sylvia Wassertheil-Smoller; Tanya N. Turan; Deidre Wentworth
The aim of this updated statement is to provide comprehensive and timely evidence-based recommendations on the prevention of ischemic stroke among survivors of ischemic stroke or transient ischemic attack. Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments for cardioembolism, and the use of antiplatelet agents for noncardioembolic stroke. Further recommendations are provided for the prevention of recurrent stroke in a variety of other specific circumstances, including arterial dissections; patent foramen ovale; hyperhomocysteinemia; hypercoagulable states; sickle cell disease; cerebral venous sinus thrombosis; stroke among women, particularly with regard to pregnancy and the use of postmenopausal hormones; the use of anticoagulation after cerebral hemorrhage; and special approaches to the implementation of guidelines and their use in high-risk populations.
Circulation | 2011
Paul A. Heidenreich; Justin G. Trogdon; Olga Khavjou; Javed Butler; Kathleen Dracup; Michael D. Ezekowitz; Eric A. Finkelstein; Yuling Hong; S. Claiborne Johnston; Amit Khera; Donald M. Lloyd-Jones; Sue A. Nelson; Graham Nichol; Diane Orenstein; Peter W.F. Wilson; Y. Joseph Woo
Background— Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results— To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008
Stroke | 2014
Walter N. Kernan; Bruce Ovbiagele; Henry R. Black; Dawn M. Bravata; Marc I. Chimowitz; Michael D. Ezekowitz; Margaret C. Fang; Marc Fisher; Karen L. Furie; Donald Heck; S. Claiborne Johnston; Scott E. Kasner; Steven J. Kittner; Pamela H. Mitchell; Michael W. Rich; DeJuran Richardson; Lee H. Schwamm; John A. Wilson
) total direct medical costs of CVD are projected to triple, from
Stroke | 2006
Ralph L. Sacco; Robert J. Adams; Greg Albers; Mark J. Alberts; Oscar Benavente; Karen L. Furie; Larry B. Goldstein; Philip B. Gorelick; Jonathan L. Halperin; Robert E. Harbaugh; S. Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J. Kenton; Michael P. Marks; Lee H. Schwamm; Thomas A. Tomsick
273 billion to
Stroke | 2001
J. Claude Hemphill; David C. Bonovich; Lavrentios Besmertis; Geoffrey T. Manley; S. Claiborne Johnston
818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from
Stroke | 2015
William J. Powers; Colin P. Derdeyn; José Biller; Christopher S. Coffey; Brian L. Hoh; Edward C. Jauch; Karen C. Johnston; S. Claiborne Johnston; Alexander A. Khalessi; Chelsea S. Kidwell; James F. Meschia; Bruce Ovbiagele; Dileep R. Yavagal
172 billion in 2010 to
Neurology | 2005
Rachel A. Whitmer; Steve Sidney; Joseph V. Selby; S. Claiborne Johnston; Kristine Yaffe
276 billion in 2030, an increase of 61%. Conclusions— These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.
Lancet Neurology | 2009
S. Claiborne Johnston; Shanthi Mendis; Colin Mathers
The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of ischemic stroke or transient ischemic attack. The guideline is addressed to all clinicians who manage secondary prevention for these patients. Evidence-based recommendations are provided for control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke. Recommendations are also provided for the prevention of recurrent stroke in a variety of specific circumstances, including aortic arch atherosclerosis, arterial dissection, patent foramen ovale, hyperhomocysteinemia, hypercoagulable states, antiphospholipid antibody syndrome, sickle cell disease, cerebral venous sinus thrombosis, and pregnancy. Special sections address use of antithrombotic and anticoagulation therapy after an intracranial hemorrhage and implementation of guidelines.
The New England Journal of Medicine | 2013
Wang Y; Yilong Wang; Xingquan Zhao; Liping Liu; David Wang; Chunxue Wang; Chen Wang; Hao Li; Xia Meng; Liying Cui; Jianping Jia; Qiang Dong; Anding Xu; Jinsheng Zeng; Yan-Sheng Li; Zhimin Wang; Haiqin Xia; S. Claiborne Johnston
The aim of this new statement is to provide comprehensive and timely evidence-based recommendations on the prevention of ischemic stroke among survivors of ischemic stroke or transient ischemic attack. Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments for cardioembolism, and the use of antiplatelet agents for noncardioembolic stroke. Further recommendations are provided for the prevention of recurrent stroke in a variety of other specific circumstances, including arterial dissections; patent foramen ovale; hyperhomocysteinemia; hypercoagulable states; sickle cell disease; cerebral venous sinus thrombosis; stroke among women, particularly with regard to pregnancy and the use of postmenopausal hormones; the use of anticoagulation after cerebral hemorrhage; and special approaches for the implementation of guidelines and their use in high-risk populations.
Stroke | 2005
Lee H. Schwamm; Arthur Pancioli; Joe E. Acker; Larry B. Goldstein; Richard D. Zorowitz; Timothy J. Shephard; Peter Moyer; Mark W. Gorman; S. Claiborne Johnston; Pamela W. Duncan; Phil Gorelick; Jeffery Frank; Steven K. Stranne; Renee Smith; William Federspiel; Katie B. Horton; Ellen Magnis; Robert J. Adams
BACKGROUND AND PURPOSE Intracerebral hemorrhage (ICH) constitutes 10% to 15% of all strokes and remains without a treatment of proven benefit. Despite several existing outcome prediction models for ICH, there is no standard clinical grading scale for ICH analogous to those for traumatic brain injury, subarachnoid hemorrhage, or ischemic stroke. METHODS Records of all patients with acute ICH presenting to the University of California, San Francisco during 1997-1998 were reviewed. Independent predictors of 30-day mortality were identified by logistic regression. A risk stratification scale (the ICH Score) was developed with weighting of independent predictors based on strength of association. RESULTS Factors independently associated with 30-day mortality were Glasgow Coma Scale score (P<0.001), age >/=80 years (P=0.001), infratentorial origin of ICH (P=0.03), ICH volume (P=0.047), and presence of intraventricular hemorrhage (P=0.052). The ICH Score was the sum of individual points assigned as follows: GCS score 3 to 4 (=2 points), 5 to 12 (=1), 13 to 15 (=0); age >/=80 years yes (=1), no (=0); infratentorial origin yes (=1), no (=0); ICH volume >/=30 cm(3) (=1), <30 cm(3) (=0); and intraventricular hemorrhage yes (=1), no (=0). All 26 patients with an ICH Score of 0 survived, and all 6 patients with an ICH Score of 5 died. Thirty-day mortality increased steadily with ICH Score (P<0.005). CONCLUSIONS The ICH Score is a simple clinical grading scale that allows risk stratification on presentation with ICH. The use of a scale such as the ICH Score could improve standardization of clinical treatment protocols and clinical research studies in ICH.